Actively Recruiting
DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients Analyzing Guideline-Concordant Care in First-line Treatment Patterns Observational Study
Led by AstraZeneca · Updated on 2026-05-13
200
Participants Needed
7
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a prospective, observational, multicenter study to collect and analyze clinical and demographic data from patients with advanced non-small cell lung carcinoma (NSCLC) starting first-line oncological treatment. This study aims to describe the epidemiological characteristics of NSCLC patients in Brazil, assess treatment patterns, and evaluate how these choices align with established guidelines over an average of two years. Additionally, a survey targeting thoracic and generalist medical oncologists in Brazil will explore factors influencing treatment decisions. The study involves extracting data from electronic medical records of approximately 200 patients treated at seven participating centers between January 2025 and January 2026. Eligible patients have unresectable or metastatic NSCLC and are beginning their first-line treatment. The survey will complement this data by gathering insights from oncologists about their treatment selection processes, enabling comparison with real-world clinical data. Participants will be monitored through their medical records to collect relevant clinical and demographic information. Researchers will evaluate treatment patterns, epidemiological details, and the influence of tumor mutations and PD-L1 expression on therapy choices. The study will also analyze survey responses from oncologists to understand variations in first-line treatment decisions. The total study duration is approximately two years, encompassing data collection and analysis phases.
CONDITIONS
Brief Title
DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Advanced (unresectable or metastatic) non-small cell lung carcinoma
- Starting first-line oncological treatment at a participating center between January 2025 and January 2026
- Age over 18 years
- Data available in electronic medical records
You will not qualify if you...
- Localized disease suitable for local treatment
- Non-epithelial histology
- Small cell carcinoma
- Neuroendocrine tumor
- Patients treated with the PACIFIC protocol for unresectable NSCLC and currently under follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 2 years
Participants who undergo routine care are observed to collect data on their demographics, clinical profile, and first-line treatment patterns for non-small cell lung carcinoma.
Data collected through medical records during routine care
Trial Site Locations
Total: 7 locations
1
Research Site
Recife, Brazil
Active, Not Recruiting
2
Research Site
Rio de Janeiro, Brazil
Actively Recruiting
3
Research Site
Rio de Janeiro, Brazil
Not Yet Recruiting
4
Research Site
Salvador, Brazil
Actively Recruiting
5
Research Site
Salvador, Brazil
Not Yet Recruiting
6
Research Site
São Paulo, Brazil
Active, Not Recruiting
7
Research Site
São Paulo, Brazil
Not Yet Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here